NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on
the diagnosis and treatment of the neurological complications of
diabetes, announced the launch of www.SENSUSRx.com.
The website provides patients and physicians with a one-stop location
for information about chronic pain such as painful diabetic neuropathy
and the SENSUS™ Pain Management System. Traditional corporate website
content such as investor relations and corporate governance is also
accessible.
The SENSUS Pain Management System is a convenient and wearable
non-invasive electrical nerve stimulator that offers patients a
fast-acting, non-narcotic option for relief from chronic pain. The
device is lightweight and can be worn during the day while remaining
active, or at night while sleeping. It is specifically designed for
people with diabetes that suffer from chronic pain. The most common
cause of such pain is painful diabetic neuropathy (PDN), which affects
up to 5 million people in the U.S. alone.
www.SENSUSRx.com
contains a variety of content including interactive tools to help people
evaluate and discuss chronic pain with their physicians, video
testimonials of SENSUS users, and product support materials such as an
instructional video. The website also contains social media features
including a SENSUS blog that will point visitors to the latest relevant
research and provide updates on SENSUS and related technologies.
“This new website will provide patients and physicians easy access to
information about chronic pain, such as painful diabetic neuropathy
(PDN), and the use of SENSUS for pain relief,” said Shai N. Gozani M.D.,
Ph.D., President and Chief Executive Officer of NeuroMetrix. “PDN is a
large problem in the diabetes community. We believe that there is an
important role for SENSUS to play in managing pain due to PDN, and that
this website will be a useful tool to reach this audience. It contains a
wide range of product and disease information that we intend to further
expand over time.”
About NeuroMetrix
NeuroMetrix is a medical device company that develops and markets home
use and point-of-care devices for the treatment and management of
chronic pain, peripheral neuropathies, and associated neurological
disorders. The Company is presently focused on diabetic neuropathies,
which affect over 50% of people with diabetes. If left untreated,
diabetic neuropathies trigger foot ulcers that may require amputation
and cause disabling chronic pain. The annual cost of diabetic
neuropathies has been estimated at $14 billion in the United States. The
company markets the SENSUS™ Pain Management System for treating chronic
pain, focusing on physicians managing patients with painful diabetic
neuropathy. The company also markets the DPNCheck® device,
which is a rapid, accurate, and quantitative point-of-care test for
diabetic neuropathy. This product is used to detect diabetic neuropathy
at an early stage and to guide treatment. For more information, please
visit http://www.SENSUSRx.com.
Copyright Business Wire 2013